

Nephrology Research

Approved:	November 2023
Study:	A Phase III, Randomized, Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects with Type 2 Diabetes and Chronic Kidney Disease (Protocol – REGEN-006)
Investigators:	Thomas Wooldridge, MD (PI); Nephrology Associates
Summary:	The purpose of this study is to determine whether Renal Autologous Cell Therapy (REACT) is safe and efficacious to improve or stabilize kidney function in subjects with type 2 diabetes and chronic kidney disease.